Screener
Abbott ABT Diagnostic Products — Total Assets
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Abbott’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050134
| (in millions) | Total Assets / As of June 30, 2026 | Total Assets / As of December 31, 2025 |
|---|---|---|
| Established Pharmaceuticals | $3,819 | $3,540 |
| Nutritional Products | 5,278 | 4,791 |
| Diagnostic Products | 9,709 | 8,273 |
| Medical Devices | 11,406 | 10,689 |
| Total Reportable Segment Assets | $30,212 | $27,293 |
| Cash and investments | 6,714 | 9,857 |
| Goodwill and intangible assets | 52,455 | 29,561 |
| All other (c) | 19,834 | 20,002 |
Item 1. Financial Statements and Supplementary Data
FAQ
- What is Abbott's diagnostic products — total assets?
- Abbott (ABT) reported diagnostic products — total assets of $9.71B in Q2 2026.
- How has Abbott's diagnostic products — total assets changed year-over-year?
- Abbott's diagnostic products — total assets increased by 18.7% year-over-year, from $8.18B to $9.71B.
- What does diagnostic products — total assets mean?
- The sum of all assets, including inventory, property, plant, equipment, and intangible assets, specifically attributed to the diagnostics segment. This represents the capital base deployed to support the segment's operations and revenue generation.
Ask your AI about Abbott's diagnostic products — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude